These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients. Riis PT; Søeby K; Saunte DM; Jemec GB Arch Dermatol Res; 2015 Dec; 307(10):885-9. PubMed ID: 26350517 [TBL] [Abstract][Full Text] [Related]
11. Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial. Flora A; Jepsen R; Pham J; Frew JW J Invest Dermatol; 2024 Apr; 144(4):786-793.e1. PubMed ID: 37879397 [TBL] [Abstract][Full Text] [Related]
12. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173 [TBL] [Abstract][Full Text] [Related]
13. Eosinophils in hidradenitis suppurativa patients exhibit pro-inflammatory traits, implicating a potential pathogenic role in the disease. Renert-Yuval Y; Gonzalez J; Garcet S; Williams SC; Moreno A; Krueger JG Exp Dermatol; 2024 Jul; 33(7):e15129. PubMed ID: 38984465 [TBL] [Abstract][Full Text] [Related]
14. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Kelly G; Hughes R; McGarry T; van den Born M; Adamzik K; Fitzgerald R; Lawlor C; Tobin AM; Sweeney CM; Kirby B Br J Dermatol; 2015 Dec; 173(6):1431-9. PubMed ID: 26282467 [TBL] [Abstract][Full Text] [Related]
15. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa. Yao Y; Thomsen SF Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469692 [TBL] [Abstract][Full Text] [Related]
16. CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa. Gamell C; Bankovacki A; Scalzo-Inguanti K; Sedgmen B; Alhamdoosh M; Gail E; Turkovic L; Millar C; Johnson L; Wahlsten M; Richter J; Schuster J; Dyson A; Nicolopoulos J; Varigos G; Ng M; Wilson N; Field J; Kern JS; Lindqvist LM Br J Dermatol; 2023 Apr; 188(5):636-648. PubMed ID: 36691791 [TBL] [Abstract][Full Text] [Related]
17. Tunnels in Hidradenitis Suppurativa: Active Inflammatory Entities with Specific Molecular and Genetic Profiles - A Narrative Review. Krajewski PK; Szepietowski JC; Martorell A Dermatology; 2023; 239(3):323-327. PubMed ID: 36822156 [TBL] [Abstract][Full Text] [Related]
18. Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. Narla S; Azzam M; Townsend S; Vellaichamy G; Marzano AV; Alavi A; Lowes MA; Hamzavi IH Br J Dermatol; 2021 Jun; 184(6):1004-1013. PubMed ID: 32893875 [TBL] [Abstract][Full Text] [Related]